Ustekinumab Shows Better Persistence than Anti-TNF in IBD Patients After Vedolizumab
Author Information
Author(s): Chiu Horng-Yih, Kuo Chia-Jung, Lai Ming-Wei, Wu Ren-Chin, Chen Chien-Ming, Chiu Cheng-Tang, Pan Yu-Bin, Chiu Cheng-Hsun, Le Puo-Hsien
Primary Institution: Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan
Hypothesis
How does the treatment persistence of ustekinumab compare to anti-TNF therapies in patients with inflammatory bowel disease who have previously been treated with vedolizumab?
Conclusion
Ustekinumab demonstrated superior 52-week treatment persistence in IBD patients previously treated with vedolizumab compared to anti-TNF agents.
Supporting Evidence
- UST showed 91.67% persistence compared to 52.27% for anti-TNF.
- UST demonstrated superior persistence in both Crohn’s disease and ulcerative colitis patients.
- Independent predictors for treatment persistence included Crohn’s disease and UST treatment.
Takeaway
This study found that a medicine called ustekinumab works better for a longer time than another type of medicine called anti-TNF in patients with gut problems who have already tried a different treatment.
Methodology
This was a retrospective cohort study analyzing treatment persistence in IBD patients treated with ustekinumab or anti-TNF after vedolizumab exposure.
Potential Biases
Potential biases include clinician preferences and selection bias based on patients' baseline characteristics.
Limitations
The study is limited by its single-center design and the retrospective nature, which may introduce biases.
Participant Demographics
The study included 110 IBD patients, with 40 diagnosed with ulcerative colitis and 70 with Crohn’s disease.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 0.05–0.45
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website